Pd-1 blockade and cd27 stimulation activate distinct transcriptional programs that synergize for CD8þ T-cell–driven antitumor immunity

Clinical Cancer Research

Volumn 24, Issue 10, 2018, Pages 2383-2394

  Buchan, Sarah L ^a   Fallatah, Mohannad ^a   Thirdborough, Stephen M ^b   Taraban, Vadim Y ^a,e   Rogel, Anne ^a   Thomas, Lawrence J ^c   Penfold, Christine A ^a   He, Li Zhen ^c   Curran, Michael A ^d   Keler, Tibor ^c   Al Shamkhani, Aymen ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c Celldex Therapeutics Inc   (United Kingdom)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e SOUTHAMPTON SOLENT UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 2; MYC PROTEIN; PROGRAMMED DEATH 1 RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR BLOCKING AGENT; RECEPTOR BLOCKING AGENT; TRANSCRIPTION FACTOR T BET; TRANSCRIPTOME; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VARLILUMAB; CD27 ANTIGEN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTITUMOR IMMUNITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSCRIPTION; LYMPHOCYTE PROLIFERATION; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSCRIPTOMICS; TUMOR IMMUNITY; ANIMAL; DISEASE MODEL; DRUG EFFECT; EXPERIMENTAL MELANOMA; GENE EXPRESSION PROFILING; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOMODULATION; LYMPHOCYTE ACTIVATION; METABOLISM; NEOPLASM; TRANSGENIC MOUSE;

ADOPTIVE TRANSFER; ANIMALS; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; GENE EXPRESSION PROFILING; HUMANS; IMMUNOMODULATION; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MICE; MICE, TRANSGENIC; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; TRANSCRIPTOME; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 7;

EID: 85047835676     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-17-3057     Document Type: Article

References (53)

1. Pauken KE, Wherry EJ. Overcoming T cell exhaustion in infection and cancer. Trends Immunol 2015;36:265–76.
2. Hui E, Cheung J, Zhu J, Su X, Taylor MJ, Wallweber HA, et al. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science 2017;355:1428–33.
3. Brown KE, Freeman GJ, Wherry EJ, Sharpe AH. Role of PD-1 in regulating acute infections. Curr Opin Immunol 2010;22:397–401.
4. Fuse S, Tsai CY, Molloy MJ, Allie SR, Zhang W, Yagita H, et al. Recall responses by helpless memory CD8þ T cells are restricted by the upregulation of PD-1. J Immunol 2009;182:4244–54.
5. Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, et al. PD-1 identifies the patient-specific CD8(þ) tumor-reactive repertoire infiltrating human tumors. J Clin Invest 2014;124:2246–59.
6. Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest 2015;125:3384–91.
7. Blank CU, Haanen JB, Ribas A, Schumacher TN. CANCER IMMUNOLOGY. The "cancer immunogram". Science 2016;352:658–60.
8. Corrales L, Matson V, Flood B, Spranger S, Gajewski TF. Innate immune signaling and regulation in cancer immunotherapy. Cell Res 2017; 27:96–108.
9. Taraban VY, Rowley TF, Al-Shamkhani A. Cutting edge: a critical role for CD70 in CD8 T cell priming by CD40-licensed APCs. J Immunol 2004;173:6542–6.
10. Taraban VY, Rowley TF, Tough DF, Al-Shamkhani A. Requirement for CD70 in CD4þ Th cell-dependent and innate receptor-mediated CD8þ T cell priming. J Immunol 2006;177:2969–75.
11. Taraban VY, Martin S, Attfield KE, Glennie MJ, Elliott T, Elewaut D, et al. Invariant NKT cells promote CD8þ cytotoxic T cell responses by inducing CD70 expression on dendritic cells. J Immunol 2008;180: 4615–20.
12. French RR, Taraban VY, Crowther GR, Rowley TF, Gray JC, Johnson PW, et al. Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation. Blood 2007;109:4810–5.
13. Bak SP, Barnkob MS, Bai A, Higham EM, Wittrup KD, Chen J. Differential requirement for CD70 and CD80/CD86 in dendritic cell-mediated activation of tumor-tolerized CD8 T cells. J Immunol 2012;189: 1708–16.
14. Taraban VY, Rowley TF, Kerr JP, Willoughby JE, Johnson PM, Al-Shamkhani A, et al. CD27 costimulation contributes substantially to the expansion of functional memory CD8(þ) T cells after peptide immunization. Eur J Immunol 2013;43:3314–23.
15. Rowley TF, Al-Shamkhani A. Stimulation by soluble CD70 promotes strong primary and secondary CD8þ cytotoxic T cell responses in vivo. J Immunol 2004;172:6039–46.
16. Buchan SL, Manzo T, Flutter B, Rogel A, Edwards N, Zhang L, et al. OX40- and CD27-mediated costimulation synergizes with anti-PD-L1 blockade by forcing exhausted CD8þ T cells to exit quiescence. J Immunol 2015; 194:125–33.
17. Ahrends T, Babala N, Xiao Y, Yagita H, van Eenennaam H, Borst J. CD27 Agonism Plus PD-1 Blockade Recapitulates CD4þ T-cell Help in Therapeutic Anticancer Vaccination. Cancer Res 2016;76:2921–31.
18. Sancho D, Mourao-Sa D, Joffre OP, Schulz O, Rogers NC, Pennington DJ, et al. Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. J Clin Invest 2008;118:2098–110.
19. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 2010;107:4275–80.
20. Boyer MW, Orchard PJ, Gorden KB, Anderson PM, McLvor RS, Blazar BR. Dependency on intercellular adhesion molecule recognition and local interleukin-2 provision in generation of an in vivo CD8þ T-cell immune response to murine myeloid leukemia. Blood 1995;85:2498–506.
21. He LZ, Prostak N, Thomas LJ, Vitale L, Weidlick J, Crocker A, et al. Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice. J Immunol 2013;191: 4174–83.
22. Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8þ T cells. J Exp Med 2003; 198:569–80.
23. Willoughby JE, Kerr JP, Rogel A, Taraban VY, Buchan SL, Johnson PW, et al. Differential impact of CD27 and 4-1BB costimulation on effector and memory CD8 T cell generation following peptide immunization. J Immunol 2014;193:244–51.
24. Overwijk WW, Tsung A, Irvine KR, Parkhurst MR, Goletz TJ, Tsung K, et al. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med 1998;188:277–86.
25. Taraban VY, Rowley TF, O'Brien L, Chan HT, Haswell LE, Green MH, et al. Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses. Eur J Immunol 2002;32: 3617–27.
26. Lin GH, Snell LM, Wortzman ME, Clouthier DL, Watts TH. GITR-dependent regulation of 4-1BB expression: implications for T cell memory and anti-4-1BB-induced pathology. J Immunol 2013;190: 4627–39.
27. Snell LM, Lin GH, Watts TH. IL-15-dependent upregulation of GITR on CD8 memory phenotype T cells in the bone marrow relative to spleen and lymph node suggests the bone marrow as a site of superior bioavailability of IL-15. J Immunol 2012;188:5915–23.
28. Croft M, Duan W, Choi H, Eun SY, Madireddi S, Mehta A. TNF superfamily in inflammatory disease: translating basic insights. Trends Immunol 2012;33:144–52.
29. Sullivan BM, Juedes A, Szabo SJ, von Herrath M, Glimcher LH. Antigen-driven effector CD8 T cell function regulated by T-bet. Proc Natl Acad Sci U S A 2003;100:15818–23.
30. Peperzak V, Xiao Y, Veraar EA, Borst J. CD27 sustains survival of CTLs in virus-infected nonlymphoid tissue in mice by inducing autocrine IL-2 production. J Clin Invest 2010;120:168–78.
31. Wang R, Dillon CP, Shi LZ, Milasta S, Carter R, Finkelstein D, et al. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity 2011;35:871–82.
32. Heinzel S, Binh Giang T, Kan A, Marchingo JM, Lye BK, Corcoran LM, et al. A Myc-dependent division timer complements a cell-death timer to regulate T cell and B cell responses. Nat Immunol 2017;18:96–103.
33. DeGregori J. E2F and cell survival: context really is key. Dev Cell 2005; 9:442–4.
34. Preston GC, Sinclair LV, Kaskar A, Hukelmann JL, Navarro MN, Ferrero I, et al. Single cell tuning of Myc expression by antigen receptor signal strength and interleukin-2 in T lymphocytes. EMBO J 2015;34:2008–24.
35. Sinclair LV, Rolf J, Emslie E, Shi YB, Taylor PM, Cantrell DA. Control of amino-acid transport by antigen receptors coordinates the metabolic reprogramming essential for T cell differentiation. Nat Immunol 2013; 14:500–8.
36. Velica P, Zech M, Henson S, Holler A, Manzo T, Pike R, et al. Genetic Regulation of Fate Decisions in Therapeutic T Cells to Enhance Tumor Protection and Memory Formation. Cancer Res 2015;75:2641–52.
37. Denizot F, Brunet JF, Roustan P, Harper K, Suzan M, Luciani MF, et al. Novel structures CTLA-2 alpha and CTLA-2 beta expressed in mouse activated T cells and mast cells and homologous to cysteine proteinase proregions. Eur J Immunol 1989;19:631–5.
38. Garcia-Bernal D, Dios-Esponera A, Sotillo-Mallo E, Garcia-Verdugo R, Arellano-Sanchez N, Teixido J. RGS10 restricts upregulation by chemo-kines of T cell adhesion mediated by alpha4beta1 and alphaLbeta2 integrins. J Immunol 2011;187:1264–72.
39. Wu H, Liu G, Li C, Zhao S. bri3, a novel gene, participates in tumor necrosis factor-alpha-induced cell death. Biochem Biophys Res Commun 2003; 311:518–24.
40. Collins S, Waickman A, Basson A, Kupfer A, Licht JD, Horton MR, et al. Regulation of CD4(þ) and CD8(þ) effector responses by Sprouty-1. PLoS One 2012;7:e49801.
41. Omilusik KD, Shaw LA, Goldrath AW. Remembering one's ID/E-ntity: E/ID protein regulation of T cell memory. Curr Opin Immunol 2013;25:660–6.
42. Zhou X, Xue HH. Cutting edge: generation of memory precursors and functional memory CD8þ T cells depends on T cell factor-1 and lymphoid enhancer-binding factor-1. J Immunol 2012;189:2722–6.
43. Bronk CC, Yoder S, Hopewell EL, Yang S, Celis E, Yu XZ, et al. NF-kappaB is crucial in proximal T-cell signaling for calcium influx and NFAT activation. Eur J Immunol 2014;44:3741–6.
44. Giordano M, Roncagalli R, Bourdely P, Chasson L, Buferne M, Yamasaki S, et al. The tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20) imposes a brake on antitumor activity of CD8 T cells. Proc Natl Acad Sci U S A 2014;111:11115–20.
45. Zhong G, Cheng X, Long H, He L, Qi W, Xiang T, et al. Dynamically expressed microRNA-15b modulates the activities of CD8þ T lymphocytes in mice with Lewis lung carcinoma. J Transl Med 2013;11:71.
46. Tegla CA, Cudrici CD, Nguyen V, Danoff J, Kruszewski AM, Boodhoo D, et al. RGC-32 is a novel regulator of the T-lymphocyte cell cycle. Exp Mol Pathol 2015;98:328–37.
47. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015;27: 450–61.
48. Spranger S, Luke JJ, Bao R, Zha Y, Hernandez KM, Li Y, et al. Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma. Proc Natl Acad Sci U S A 2016;113:E7759–68.
49. Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol 2009;9:271–85.
50. Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol 2015;15:486–99.
51. Kamphorst AO, Wieland A, Nasti T, Yang S, Zhang R, Barber DL, et al. Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science 2017;355:1423–7.
52. West EE, Jin HT, Rasheed AU, Penaloza-Macmaster P, Ha SJ, Tan WG, et al. PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. J Clinical Invest 2013;123:2604–15.
53. Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 2017;545:60–5.